# Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

> **NCT01922921** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 31 (actual)

## Conditions studied

- HER2/Neu Positive
- Recurrent Breast Carcinoma
- Stage IV Breast Cancer

## Interventions

- **BIOLOGICAL:** HER-2/neu Intracellular Domain Protein
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pertuzumab
- **OTHER:** Placebo
- **BIOLOGICAL:** Polysaccharide-K
- **BIOLOGICAL:** Trastuzumab

## Key facts

- **NCT ID:** NCT01922921
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-05
- **Primary completion:** 2019-10-31
- **Final completion:** 2021-09-01
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2023-04-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01922921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01922921, "Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01922921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*